TELA Bio Inc TELA.OQ TELA.O is expected to show a rise in quarterly revenue when it reports results on March 20 for the period ending December 31 2024
The Malvern Pennsylvania-based company is expected to report a 36.3% increase in revenue to $23.166 million from $17 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for TELA Bio Inc is for a loss of 22 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for TELA Bio Inc is $9.00, above its last closing price of $2.43.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.42
-0.40
-0.42
Missed
-3.9
Jun. 30 2024
-0.46
-0.47
-0.51
Missed
-8.1
Mar. 31 2024
-0.51
-0.50
-0.23
Beat
54.1
Dec. 31 2023
-0.42
-0.43
-0.53
Missed
-21.9
Sep. 30 2023
-0.49
-0.49
-0.45
Beat
8.5
Jun. 30 2023
-0.53
-0.53
-0.46
Beat
13.7
Mar. 31 2023
-0.56
-0.56
-0.63
Missed
-12.7
Dec. 31 2022
-0.51
-0.55
-0.52
Beat
4.8
This summary was machine generated March 18 at 20:26 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)